Sustained virological response following chronic hepatitis C treatment is associated with improvement in insulin resistance

Internal Medicine Journal

Volumn 43, Issue 6, 2013, Pages 656-662

  Chan, C H Y ^a   Hansen, R D ^a   Gilliver, R S ^a   Jones, B E ^a  

^a ROYAL NORTH SHORE HOSPITAL   (Australia)

Author keywords

Hepatitis C; Insulin resistance; Liver cirrhosis

Indexed keywords

ALANINE AMINOTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE; PEGINTERFERON ALPHA2A; RIBAVIRIN;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CLINICAL ASSESSMENT TOOL; CLINICAL PRACTICE; FEMALE; HEPATITIS C; HISTOLOGY; HOMEOSTATIC MODEL ASSESSMENT INSULIN RESISTANCE; HUMAN; INSULIN RESISTANCE; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROSPECTIVE STUDY; TEACHING HOSPITAL; VIRAL CLEARANCE;

ADULT; ANTIVIRAL AGENTS; COHORT STUDIES; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INSULIN RESISTANCE; INTERFERON-ALPHA; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RIBAVIRIN; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84879023939     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/imj.12136     Document Type: Article

References (37)

1. Asselah T, Rubbia-Brandt L, Marcellin P, Negro F. Steatosis in chronic hepatitis C: why does it really matter? Gut 2006; 55: 123-130.
2. Yazicioglu G, Isitan F, Altunbas H, Suleymanlar I, Ozdogan M, Balci MK etal. Insulin resistance in chronic hepatitis C. Int J Clin Pract 2004; 58: 1020-1022.
3. Negro F, Sanyal AJ. Hepatitis C virus, steatosis and lipid abnormalities: clinical and pathogenic data. Liver Int 2009; 29(Suppl 2): 26-37.
4. Hui JM, Sud A, Farrell GC, Bandara P, Byth K, Kench JG etal. Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression [corrected]. Gastroenterology 2003; 125: 1695-1704.
5. Ratziu V, Heurtier A, Bonyhay L, Poynard T, Giral P. Review article: an unexpected virus-host interaction - the hepatitis C virus-diabetes link. Aliment Pharmacol Ther 2005; 22(Suppl 2): 56-60.
6. Shintani Y, Fujie H, Miyoshi H, Tsutsumi T, Tsukamoto K, Kimura S etal. Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. Gastroenterology 2004; 126: 840-848.
7. Castera L, Hezode C, Roudot-Thoraval F, Bastie A, Zafrani ES, Pawlotsky JM etal. Worsening of steatosis is an independent factor of fibrosis progression in untreated patients with chronic hepatitis C and paired liver biopsies. Gut 2003; 52: 288-292.
8. Davila JA, Morgan RO, Shaib Y, McGlynn KA, El-Serag HB. Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study. Gut 2005; 54: 533-539.
9. Nagao Y, Kawaguchi T, Tanaka K, Kumashiro R, Sata M. Extrahepatic manifestations and insulin resistance in an HCV hyperendemic area. Int J Mol Med 2005; 16: 291-296.
10. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R etal. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-965.
11. Suppiah V, Gaudieri S, Armstrong NJ, O'Connor KS, Berg T, Weltman M etal. IL28B, HLA-C, and KIR variants additively predict response to therapy in chronic hepatitis C virus infection in a European Cohort: a cross-sectional study. PLoS Med 2011; 8: e1001092.
12. Afdhal NH, McHutchison JG, Zeuzem S, Mangia A, Pawlotsky JM, Murray JS etal. Hepatitis C pharmacogenetics: state of the art in 2010. Hepatology 2011; 53: 336-345.
13. Bressler BL, Guindi M, Tomlinson G, Heathcote J. High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. Hepatology 2003; 38: 639-644.
14. Poynard T, Ratziu V, McHutchison J, Manns M, Goodman Z, Zeuzem S etal. Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology 2003; 38: 75-85.
15. Patton HM, Patel K, Behling C, Bylund D, Blatt LM, Vallee M etal. The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients. J Hepatol 2004; 40: 484-490.
16. Romero-Gomez M, Del Mar Viloria M, Andrade RJ, Salmeron J, Diago M, Fernandez-Rodriguez CM etal. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 2005; 128: 636-641.
17. Romero-Gomez M. Insulin resistance and hepatitis C. World J Gastroenterol 2006; 12: 7075-7080.
18. Cua IH, Hui JM, Bandara P, Kench JG, Farrell GC, McCaughan GW etal. Insulin resistance and liver injury in hepatitis C is not associated with virus-specific changes in adipocytokines. Hepatology 2007; 46: 66-73.
19. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419.
20. Cua IH, Hui JM, Kench JG, George J. Genotype-specific interactions of insulin resistance, steatosis, and fibrosis in chronic hepatitis C. Hepatology 2008; 48: 723-731.
21. Fartoux L, Poujol-Robert A, Guechot J, Wendum D, Poupon R, Serfaty L. Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C. Gut 2005; 54: 1003-1008.
22. Sud A, Hui JM, Farrell GC, Bandara P, Kench JG, Fung C etal. Improved prediction of fibrosis in chronic hepatitis C using measures of insulin resistance in a probability index. Hepatology 2004; 39: 1239-1247.
23. Moucari R, Asselah T, Cazals-Hatem D, Voitot H, Boyer N, Ripault MP etal. Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis. Gastroenterology 2008; 134: 416-423.
24. Thompson AJ, Patel K, Chuang WL, Lawitz EJ, Rodriguez-Torres M, Rustgi VK etal. Viral clearance is associated with improved insulin resistance in genotype 1 chronic hepatitis C but not genotype 2/3. Gut 2012; 61: 128-134.
25. Caronia S, Taylor K, Pagliaro L, Carr C, Palazzo U, Petrik J etal. Further evidence for an association between non-insulin-dependent diabetes mellitus and chronic hepatitis C virus infection. Hepatology 1999; 30: 1059-1063.
26. Albright ESB, David SH. The liver, liver disease and diabetes mellitis. Endocrinologist 2003; 13: 58-66.
27. Kawaguchi T, Yoshida T, Harada M, Hisamoto T, Nagao Y, Ide T etal. Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signaling 3. Am J Pathol 2004; 165: 1499-1508.
28. Delgado-Borrego A, Jordan SH, Negre B, Healey D, Lin W, Kamegaya Y etal. Reduction of insulin resistance with effective clearance of hepatitis C infection: results from the HALT-C trial. Clin Gastroenterol Hepatol 2010; 8: 458-462.
29. Kawaguchi T, Ide T, Taniguchi E, Hirano E, Itou M, Sumie S etal. Clearance of HCV improves insulin resistance, beta-cell function, and hepatic expression of insulin receptor substrate 1 and 2. Am J Gastroenterol 2007; 102: 570-576.
30. Kim HJ, Park JH, Park DI, Cho YK, Sohn CI, Jeon WK etal. Clearance of HCV by combination therapy of pegylated interferon alpha-2a and ribavirin improves insulin resistance. Gut Liver 2009; 3: 108-115.
31. Kawaguchi Y, Mizuta T, Oza N, Takahashi H, Ario K, Yoshimura T etal. Eradication of hepatitis C virus by interferon improves whole-body insulin resistance and hyperinsulinaemia in patients with chronic hepatitis C. Liver Int 2009; 29: 871-877.
32. Dai CY, Huang JF, Hsieh MY, Hou NJ, Lin ZY, Chen SC etal. Insulin resistance predicts response to peginterferon-alpha/ribavirin combination therapy in chronic hepatitis C patients. J Hepatol 2009; 50: 712-718.
33. McCartney EM, Semendric L, Helbig KJ, Hinze S, Jones B, Weinman SA etal. Alcohol metabolism increases the replication of hepatitis C virus and attenuates the antiviral action of interferon. J Infect Dis 2008; 198: 1766-1775.
34. Petrides AS, Vogt C, Schulze-Berge D, Matthews D, Strohmeyer G. Pathogenesis of glucose intolerance and diabetes mellitus in cirrhosis. Hepatology 1994; 19: 616-627.
35. Matos CA, Perez RM, Pacheco MS, Figueiredo-Mendes CG, Lopes-Neto E, Oliveira EB, Jr. etal. Steatosis in chronic hepatitis C: relationship to the virus and host risk factors. J Gastroenterol Hepatol 2006; 21: 1236-1239.
36. Muzzi A, Leandro G, Rubbia-Brandt L, James R, Keiser O, Malinverni R etal. Insulin resistance is associated with liver fibrosis in non-diabetic chronic hepatitis C patients. J Hepatol 2005; 42: 41-46.
37. Rubbia-Brandt L, Giostra E, Mentha G, Quadri R, Negro F. Expression of liver steatosis in hepatitis C virus infection and pattern of response to alpha-interferon. J Hepatol 2001; 35: 307.